Sanofi
Global pharma company; vaccines and R&D
Computer Science Dual Study - Bachelor of Science
Hybrid work may be available up to 60% within Germany, depending on the assignment.
About the job
- A good general or subject-specific university entrance qualification is required.
- Good spoken and written German and English skills are required.
- The candidate should have an interest in mathematics, scientific questions, information technology, and learning and applying artificial intelligence methods.
- The candidate should be comfortable working carefully with large datasets.
- The candidate should demonstrate independent working ability, communication skills, initiative, analytical thinking, adaptability, and willingness to learn.
- The candidate should be able to work effectively with customers and in teams.
- Attend in-person lectures at Provadis Hochschule to acquire theoretical knowledge and apply it in the department several days per week.
- Contribute as a full team member to the management, analysis, and visualization of complex scientific data.
- Apply machine learning and artificial intelligence in data analysis.
- Independently implement digital workflows in coordination with users.
- Use programming and scripting languages to develop workflows and work with databases.
- Support research activities and contribute independently to projects in computer-aided drug discovery.
- Track projects independently from concept development through solution matrices to decision-making.
- Coordinate with stakeholders and users to implement the best solution.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sanofi completed Vicebio on December 4, 2025, adding RSV-HMPV vaccine technology.
- Sanofi completed Dynavax on February 10, 2026, expanding hepatitis B and shingles assets.
- FDA approved wearable Sarclisa on July 2026, improving multiple myeloma convenience.
What critics are saying
- Dupixent loses patent exclusivity in 2031, exposing Sanofi’s cash engine.
- EU regulators opened a June 26, 2026 antitrust probe over Efluelda marketing.
- Sanofi sued Pfizer and Moderna on July 15, 2026 over COVID-shot patents.
What makes Sanofi unique
- Dupixent and partner Regeneron still anchor Sanofi’s immunology franchise in 2026.
- Vicebio’s Molecular Clamp and Dynavax deepen Sanofi’s respiratory and adult vaccine platform.
- Frankfurt insulin manufacturing, backed by Germany’s 2026 subsidy, protects European supply security.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...